J Torres1,2, C Palmela1, H Brito3, X Bao4, H Ruiqi5, P Moura-Santos6, J Pereira da Silva7, A Oliveira8, C Vieira9, K Perez10, S H Itzkowitz2, J F Colombel2, L Humbert10, D Rainteau10, M Cravo1, C M Rodrigues3, J Hu4. 1. Surgical Department, Hospital Beatriz Ângelo, Loures, Portugal. 2. Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, USA. 3. Research Institute for Medicines (iMed.ULisboa), Universidade de Lisboa, Lisbon, Portugal. 4. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, USA. 5. Department of Health Evidence and Policy, Icahn School of Medicine at Mount Sinai, New York, USA. 6. Gastroenterology and Hepatology Division, Hospital de Santa Maria, Lisboa, Portugal. 7. Department of Gastroenterology, Instituto Português de Oncologia de Lisboa, Portugal. 8. Department of Gastroenterology, Hospital Professor Doutor Fernando Fonseca, Amadora, Portugal. 9. Department of Gastroenterology, Centro Hospitalar Barreiro Montijo, Portugal. 10. INSERM ERL1157, Sorbonne Université - UPMC Univ Paris 06, Paris, France.
Abstract
BACKGROUND: Patients with primary sclerosing cholangitis associated with inflammatory bowel disease (PSC-IBD) have a very high risk of developing colorectal neoplasia. Alterations in the gut microbiota and/or gut bile acids could account for the increase in this risk. However, no studies have yet investigated the net result of cholestasis and a potentially altered bile acid pool interacting with a dysbiotic gut flora in the inflamed colon of PSC-IBD. AIM: The aim of this study was to compare the gut microbiota and stool bile acid profiles, as well as and their correlation in patients with PSC-IBD and inflammatory bowel disease alone. METHODS: Thirty patients with extensive colitis (15 with concomitant primary sclerosing cholangitis) were prospectively recruited and fresh stool samples were collected. The microbiota composition in stool was profiled using bacterial 16S rRNA sequencing. Stool bile acids were assessed by high-performance liquid chromatography tandem mass spectrometry. RESULTS: The total stool bile acid pool was significantly reduced in PSC-IBD. Although no major differences were observed in the individual bile acid species in stool, their overall combination allowed a good separation between PSC-IBD and inflammatory bowel disease. Compared with inflammatory bowel disease alone, PSC-IBD patients demonstrated a different gut microbiota composition with enrichment in Ruminococcus and Fusobacterium genus compared with inflammatory bowel disease. At the operational taxonomic unit level major shifts were observed within the Firmicutes (73%) and Bacteroidetes phyla (17%). Specific microbiota-bile acid correlations were observed in PSC-IBD, where 12% of the operational taxonomic units strongly correlated with stool bile acids, compared with only 0.4% in non-PSC-IBD. CONCLUSIONS: Patients with PSC-IBD had distinct microbiota and microbiota-stool bile acid correlations as compared with inflammatory bowel disease. Whether these changes are associated with, or may predispose to, an increased risk of colorectal neoplasia needs to be further clarified.
BACKGROUND: Patients with primary sclerosing cholangitis associated with inflammatory bowel disease (PSC-IBD) have a very high risk of developing colorectal neoplasia. Alterations in the gut microbiota and/or gut bile acids could account for the increase in this risk. However, no studies have yet investigated the net result of cholestasis and a potentially altered bile acid pool interacting with a dysbiotic gut flora in the inflamed colon of PSC-IBD. AIM: The aim of this study was to compare the gut microbiota and stool bile acid profiles, as well as and their correlation in patients with PSC-IBD and inflammatory bowel disease alone. METHODS: Thirty patients with extensive colitis (15 with concomitant primary sclerosing cholangitis) were prospectively recruited and fresh stool samples were collected. The microbiota composition in stool was profiled using bacterial 16S rRNA sequencing. Stool bile acids were assessed by high-performance liquid chromatography tandem mass spectrometry. RESULTS: The total stool bile acid pool was significantly reduced in PSC-IBD. Although no major differences were observed in the individual bile acid species in stool, their overall combination allowed a good separation between PSC-IBD and inflammatory bowel disease. Compared with inflammatory bowel disease alone, PSC-IBD patients demonstrated a different gut microbiota composition with enrichment in Ruminococcus and Fusobacterium genus compared with inflammatory bowel disease. At the operational taxonomic unit level major shifts were observed within the Firmicutes (73%) and Bacteroidetes phyla (17%). Specific microbiota-bile acid correlations were observed in PSC-IBD, where 12% of the operational taxonomic units strongly correlated with stool bile acids, compared with only 0.4% in non-PSC-IBD. CONCLUSIONS: Patients with PSC-IBD had distinct microbiota and microbiota-stool bile acid correlations as compared with inflammatory bowel disease. Whether these changes are associated with, or may predispose to, an increased risk of colorectal neoplasia needs to be further clarified.
Entities:
Keywords:
Gut microbiota; bile acids; inflammatory bowel disease; primary sclerosing cholangitis
Authors: Malte Christoph Rühlemann; Femke-Anouska Heinsen; Roman Zenouzi; Wolfgang Lieb; Andre Franke; Christoph Schramm Journal: Gut Date: 2016-05-23 Impact factor: 23.059
Authors: James D Lewis; Shaokun Chuai; Lisa Nessel; Gary R Lichtenstein; Faten N Aberra; Jonas H Ellenberg Journal: Inflamm Bowel Dis Date: 2008-12 Impact factor: 5.325
Authors: Martin Kummen; Kristian Holm; Jarl Andreas Anmarkrud; Ståle Nygård; Mette Vesterhus; Marte L Høivik; Marius Trøseid; Hanns-Ulrich Marschall; Erik Schrumpf; Bjørn Moum; Helge Røsjø; Pål Aukrust; Tom H Karlsen; Johannes R Hov Journal: Gut Date: 2016-02-17 Impact factor: 23.059
Authors: Aldo J Montano-Loza; Jessica R Allegretti; Angela Cheung; Maryam Ebadi; David Jones; Nanda Kerkar; Cynthia Levy; Sumera Rizvi; John M Vierling; Fernando Alvarez; Wayne Bai; Susan Gilmour; Aliya Gulamhusein; Orlee Guttman; Bettina E Hansen; Sonya MacParland; Andrew Mason; Fernanda Onofrio; Pere Santamaria; Ashley Stueck; Mark Swain; Catherine Vincent; Amanda Ricciuto; Gideon Hirschfield Journal: Can Liver J Date: 2021-11-11
Authors: Mohammed Nabil Quraishi; Animesh Acharjee; Andrew D Beggs; Richard Horniblow; Chris Tselepis; Georgios Gkoutos; Subrata Ghosh; A E Rossiter; Nicholas Loman; Willem van Schaik; David Withers; Julian R F Walters; Gideon M Hirschfield; Tariq H Iqbal Journal: J Crohns Colitis Date: 2020-07-30 Impact factor: 9.071
Authors: Byron P Vaughn; Thomas Kaiser; Christopher Staley; Matthew J Hamilton; Jon Reich; Carolyn Graiziger; Stephanie Singroy; Amanda J Kabage; Michael J Sadowsky; Alexander Khoruts Journal: Clin Exp Gastroenterol Date: 2019-01-10